l
The SwissHTA initiative involving all key stakeholders in the healthcare systems (sickness funds, industry, physicians, academia, Kantons) has published consensus papers for new benefit criteria and measurements.
METHODS:
l A comparison was executed comparing the new proposed criteria against benefit assessments in HTA systems in Germany and the UK. The following pricing and reimbursement (P&R) agencies were screened for their P&R guidance: -Bundesamt für Gesundheit (BAG; Federal Agency for Health), Switzerland.
-Gemeinsamer Bundesausschuss (G-BA; Joint federal committee), Germany.
-Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG; Institute for Quality and Efficiency in health care), Germany -National Institute of Clinical Excellence (NICE), UK. Additionally the recommendation for a new benefit assessment in Switzerland suggested by the SwissHTA was screened and evaluated. The following items were selected for a comparison between the different health care reimbursement systems: -Clinical effectiveness assessment.
• Is there a clear and transparent process in place?
• Does the process follow accepted evidence-based methods? -Health Economic assessment.
• What is the health economic requirement for a standard P&R process?
• What are the health economic measures?
• How strict is the health economic evidence requirement for the reimbursement decision applied?
RESULTS:
Reimbursement processes: l In comparison to Germany the Swiss approach suggests a pragmatic application by applying disease specific standards. For example these standards could be endpoints dedicated to the disease itself also allowing for surrogate endpoints. This disease focus allows also accepting different levels of evidence given the characteristics of a respective disease.
l Further, this pragmatic approach allows Swiss decision-makers accepting lower evidence levels at the time of launch (e.g. in case of comparison with non-Swiss standard-of-care) coupled with a post-reimbursement commitment (e.g. post-reimbursement clinical trial or country specific prospective patient data collection). 
Health Economic assessment

